INDUSTRY OVERVIEW
The Liquid Tumor Biopsy is Growing at 14.00% and is expected to reach USD5Billion by 2030. Below mentioned are some of the dynamics shaping the Liquid Tumor Biopsy .Liquid Tumor Biopsy Market Size in (USD Billion) CAGR Growth Rate 14.00%
| Study Period | 2019-2030 |
| Market Size (2023): | USD2Billion |
| Market Size (2030): | USD5Billion |
| CAGR (2023 - 2030): | 14.00% |
| Fastest Growing Region | North America |
| Dominating Region | Europe |
www.htfmarketinsights.com
Non-invasive diagnostic tests that analyze bodily fluids to detect cancer markers.
Need More Details on Market Players and Competitors?
DOWNLOAD Sample Report
Market Drivers:
The key drivers in the market include technological advancements, increasing demand by consumers for innovative products, and government-friendly policies. Our research company combines industry reports with expert interviews and market analysis tools to identify and quantify drivers such as these. We review the current trends and gather data from leading industry publications and market research firms to decipher exactly how these and other factors are encouraging or dampening market growth.
- Adoption Of Liquid Biopsy For Early-stage Cancer Detection
Market Restraints:
Some of the restraints to market growth may include regulatory challenges, high production costs, and disruptions in the supply chain. Our sources for these limitations include the regulation filings, industry surveys, and direct contributions from active participants within this marketplace. Tracking policy updates and economic reports further helps us to determine what kind of effect these factors have on the industry.
- Regulatory Approval Hurdles
Trends in the Market:
Among the trending ones are sustainability, digital transformation, and increasing importance of data analytics. Our research company is tracking these trends through the use of trend analysis tools, social media sentiment analysis, and industry benchmarking studies. Insights in emerging market preferences and technological advancements also come from surveys and focus groups.
- Shift towards non-invasive diagnostics
Market Opportunities:
These include emerging markets, innovation in product development, and strategic partnerships. We identify these opportunities by performing market segmentation analysis, competitive landscape assessment, and investment trend evaluation. The data is collected based on industry reports, financial performance analysis for major players, and forecasting models for identifying future growth areas.
- Adoption Of Liquid Biopsy For Early-stage Cancer Detection
Check Out Prices
Get Price
Regulation Shaping the Healthcare Industry
The healthcare industry is significantly influenced by a complex framework of regulations designed to ensure patient safety, efficacy of treatments, and the overall quality of care. Key regulatory areas include drug approval processes, medical device standards, and healthcare data protection. These regulations aim to maintain high standards for clinical practices and safeguard public health.Major Regulatory Bodies Worldwide
1. U.S. Food and Drug Administration (FDA): In the United States, the FDA is a pivotal regulatory authority overseeing the approval and monitoring of pharmaceuticals, medical devices, and biologics. The FDA sets stringent standards for product safety and efficacy, which significantly impacts market entry and ongoing compliance for healthcare companies.2. European Medicines Agency (EMA): The EMA plays a crucial role in the European Union, evaluating and supervising medicinal products. It provides centralized approval for drugs and ensures that products meet rigorous safety and efficacy standards across member states.
3. Health Canada: This agency regulates pharmaceuticals and medical devices in Canada, ensuring that products are safe, effective, and of high quality. Health Canada's regulations are aligned with international standards but tailored to meet national health needs.
4. World Health Organization (WHO): While not a regulatory body in the traditional sense, the WHO sets international health standards and provides guidelines that influence national regulatory frameworks. It plays a key role in global health policy and emergency response.
5. National Medical Products Administration (NMPA): In China, the NMPA regulates the approval and supervision of drugs and medical devices, with an increasing focus on aligning with global standards and facilitating market access.
Request for Customization
Get Customization
SWOT Analysis in the Healthcare Industry
SWOT analysis in the healthcare industry involves a structured assessment of Strengths, Weaknesses, Opportunities, and Threats to identify strategic advantages and areas for improvement.• Strengths: Evaluates internal factors such as advanced technology, skilled personnel, and strong brand reputation. For example, a hospital with cutting-edge medical equipment and specialized staff is considered to have a strong competitive edge.
• Weaknesses: Identifies internal limitations like outdated facilities, regulatory compliance issues, or high operational costs. Weaknesses could include inefficient processes or lack of innovation.
• Opportunities: Assesses external factors that could drive growth, such as emerging medical technologies, expanding markets, or favorable government policies. Opportunities might involve partnerships or new service lines.
• Threats: Examines external challenges such as increasing competition, changing regulations, or economic downturns. Threats might include new entrants with disruptive technologies or stricter regulatory requirements.
Market Segmentation
Segmentation by Type
- Circulating Tumor Cells (CTC)
- ctDNA
- Exosomes
- Liquid Biopsy Platforms
Liquid Tumor Biopsy Market Segmentation by Type
www.htfmarketinsights.com
Segmentation by Application
- Cancer Diagnosis
- Personalized Medicine
- Research
- Clinical Trials
Liquid Tumor Biopsy Market Segmentation by Application
www.htfmarketinsights.com
Regional Outlook
The Europe currently holds a significant share of the market, primarily due to several key factors: increasing consumption rates, a burgeoning population, and robust economic momentum. These elements collectively drive demand, positioning this region as a leader in the market. On the other hand, North America is rapidly emerging as the fastest-growing area within the industry. This remarkable growth can be attributed to swift infrastructure development, the expansion of various industrial sectors, and a marked increase in consumer demand. These dynamics make this region a crucial player in shaping future market growth. In our report, we cover a comprehensive analysis of the regions and countries, includingRegions
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
Fastest Growing Region
North America
Dominating Region
Europe
The company consistently allocates significant resources to expand its research capabilities, develop new medical technologies, and enhance its pharmaceutical portfolio. Johnson & Johnson's investments in R&D, coupled with strategic acquisitions and partnerships, reinforce its position as a major contributor to advancements in healthcare. This focus on innovation and market expansion underscores the critical importance of the North American region in the global healthcare landscape.
- Guardant Health
- GRAIL
- Foundation Medicine
- Biocept
- Cynvenio
- Exact Sciences
- Veracyte
- Caris Life Sciences
- Sysmex
- NeoGenomics
- Roche
- Illumina
- Thermo Fisher Scientific
- Qiagen
Liquid Tumor Biopsy Market Segmentation by Players
www.htfmarketinsights.com
Primary and Secondary Research
Primary research involves the collection of original data directly from sources in the healthcare industry. Approaches include the survey of health professionals, interviews with patients, focus groups, and clinical trials. This gives an overview of the current practice, the needs of the patient, and the interest in emerging trends. Firsthand information on the efficacy of new treatments, an assessment of market demand, and insight into changes in regulation can be sought only with primary research.Secondary Research: This is the investigation of existing information from a variety of sources, which may include industry reports, academic journals, government publications, and market research studies. Alfred secondary research empowers them to understand trends within industries, historical data, and competitive landscapes. It gives a wide view of the market dynamics and validates findings obtained from primary research. By combining both primary and secondary together, health organizations will be empowered to develop comprehensive strategies and make informed decisions based on a strong foundation built on data.
Report Infographics
|
Report Features |
Details |
|
Base Year |
2023 |
|
Based Year Market Size (2023) |
USD2Billion |
|
Historical Period |
2019 to 2023 |
|
CAGR (2023 to 2030) |
14.00% |
|
Forecast Period |
2023 to 2030 |
|
Forecasted Period Market Size (2030) |
USD5Billion |
|
Scope of the Report |
Segmentation by Type Circulating Tumor Cells (CTC), ctDNA, Exosomes, Liquid Biopsy Platforms, Segmentation by Application Cancer Diagnosis, Personalized Medicine, Research, Clinical Trials, Sales Channel |
|
Regions Covered |
North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA |
|
Companies Covered |
Guardant Health, GRAIL, Foundation Medicine, Biocept, Cynvenio, Exact Sciences, Veracyte, Caris Life Sciences, Sysmex, NeoGenomics, Roche, Illumina, Thermo Fisher Scientific, Qiagen |
|
Customization Scope |
15% Free Customization (For EG) |
|
Delivery Format |
PDF and Excel through Email |
Liquid Tumor Biopsy - Table of Contents
Chapter 1: Market Preface
- 1.1 Global Liquid Tumor Biopsy Market Landscape
- 1.2 Scope of the Study
- 1.3 Relevant Findings & Stakeholder Advantages
Chapter 2: Strategic Overview
- 2.1 Global Liquid Tumor Biopsy Market Outlook
- 2.2 Total Addressable Market versus Serviceable Market
- 2.3 Market Rivalry Projection
Chapter 3 : Global Liquid Tumor Biopsy Market Business Environment & Changing Dynamics
-
3.1 Growth Drivers
- 3.1.1 Adoption of liquid biopsy for early-stage cancer detection
-
3.2 Available Opportunities
- 3.2.1 Adoption of liquid biopsy for early-stage cancer detection
- 3.2.2 integration with AI technologies
-
3.3 Influencing Trends
- 3.3.1 Shift towards non-invasive diagnostics
- 3.3.2 development of personalized therapies
-
3.4 Challenges
- 3.4.1 Regulatory approval hurdles
- 3.4.2 high cost of tests
- 3.5 Regional Dynamics
Need only Qualitative Analysis? Get Prices
Sectional Purchase
Chapter 4 : Global Liquid Tumor Biopsy Industry Factors Assessment
- 4.1 Current Scenario
- 4.2 PEST Analysis
- 4.3 Business Environment - PORTER 5-Forces Analysis
- 4.3.1 Supplier Leverage
- 4.3.2 Bargaining Power of Buyers
- 4.3.3 Threat of Substitutes
- 4.3.4 Threat from New Entrant
- 4.3.5 Market Competition Level
- 4.4 Roadmap of Liquid Tumor Biopsy Market
- 4.5 Impact of Macro-Economic Factors
- 4.6 Market Entry Strategies
- 4.7 Political and Regulatory Landscape
- 4.8 Supply Chain Analysis
- 4.9 Impact of Tariff War
Chapter 5: Liquid Tumor Biopsy : Competition Benchmarking & Performance Evaluation
- 5.1 Global Liquid Tumor Biopsy Market Concentration Ratio
- 5.1.1 CR4, CR8 and HH Index
- 5.1.2 % Market Share - Top 3
- 5.1.3 Market Holding by Top 5
- 5.2 Market Position of Manufacturers by Liquid Tumor Biopsy Revenue 2023
- 5.3 Global Liquid Tumor Biopsy Sales Volume by Manufacturers (2023)
- 5.4 BCG Matrix
- 5.4 Market Entropy
- 5.5 Ansoff Matrix
- 5.6 FPNV Positioning Matrix
Chapter 6: Global Liquid Tumor Biopsy Market: Company Profiles
- 6.1 Guardant Health
- 6.1.1 Guardant Health Company Overview
- 6.1.2 Guardant Health Product/Service Portfolio & Specifications
- 6.1.3 Guardant Health Key Financial Metrics
- 6.1.4 Guardant Health SWOT Analysis
- 6.1.5 Guardant Health Development Activities
- 6.2 GRAIL
- 6.3 Foundation Medicine
- 6.4 Biocept
- 6.5 Cynvenio
- 6.6 Exact Sciences
- 6.7 Veracyte
- 6.8 Caris Life Sciences
- 6.9 Sysmex
- 6.10 NeoGenomics
- 6.11 Roche
- 6.12 Illumina
- 6.13 Thermo Fisher Scientific
- 6.14 Qiagen
- 6.15 ArcherDX
To View a Complete List of Players? Inquiry Now
Sectional Purchase
Chapter 7 : Global Liquid Tumor Biopsy by Type & Application (2019-2030)
-
7.1 Global Liquid Tumor Biopsy Market Revenue Analysis (USD Million) by Type (2019-2023)
- 7.1.1 Circulating Tumor Cells (CTC)
- 7.1.2 CtDNA
- 7.1.3 Exosomes
- 7.1.4 Liquid Biopsy Platforms
- 7.1.5 NGS-based Platforms
-
7.2 Global Liquid Tumor Biopsy Market Revenue Analysis (USD Million) by Application (2019-2023)
- 7.2.1 Cancer Diagnosis
- 7.2.2 Personalized Medicine
- 7.2.3 Research
- 7.2.4 Clinical Trials
- 7.3 Global Liquid Tumor Biopsy Market Revenue Analysis (USD Million) by Type (2023-2030)
- 7.4 Global Liquid Tumor Biopsy Market Revenue Analysis (USD Million) by Application (2023-2030)
Chapter 8 : North America Liquid Tumor Biopsy Market Breakdown by Country, Type & Application
- 8.1 North America Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 8.1.1 United States
- 8.1.2 Canada
-
8.2 North America Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 8.2.1 Circulating Tumor Cells (CTC)
- 8.2.2 CtDNA
- 8.2.3 Exosomes
- 8.2.4 Liquid Biopsy Platforms
- 8.2.5 NGS-based Platforms
-
8.3 North America Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 8.3.1 Cancer Diagnosis
- 8.3.2 Personalized Medicine
- 8.3.3 Research
- 8.3.4 Clinical Trials
- 8.4 North America Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2024-2030]
- 8.5 North America Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2024-2030]
- 8.6 North America Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2024-2030]
Looking for Section Purchase? Get Quote Now
Sectional Purchase
Chapter 9 : LATAM Liquid Tumor Biopsy Market Breakdown by Country, Type & Application
- 9.1 LATAM Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 9.1.1 Brazil
- 9.1.2 Argentina
- 9.1.3 Chile
- 9.1.4 Mexico
- 9.1.5 Rest of LATAM
-
9.2 LATAM Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 9.2.1 Circulating Tumor Cells (CTC)
- 9.2.2 CtDNA
- 9.2.3 Exosomes
- 9.2.4 Liquid Biopsy Platforms
- 9.2.5 NGS-based Platforms
-
9.3 LATAM Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 9.3.1 Cancer Diagnosis
- 9.3.2 Personalized Medicine
- 9.3.3 Research
- 9.3.4 Clinical Trials
- 9.4 LATAM Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2024-2030]
- 9.5 LATAM Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2024-2030]
- 9.6 LATAM Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2024-2030]
Chapter 10 : West Europe Liquid Tumor Biopsy Market Breakdown by Country, Type & Application
- 10.1 West Europe Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 10.1.1 Germany
- 10.1.2 France
- 10.1.3 Benelux
- 10.1.4 Switzerland
- 10.1.5 Rest of West Europe
-
10.2 West Europe Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 10.2.1 Circulating Tumor Cells (CTC)
- 10.2.2 CtDNA
- 10.2.3 Exosomes
- 10.2.4 Liquid Biopsy Platforms
- 10.2.5 NGS-based Platforms
-
10.3 West Europe Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 10.3.1 Cancer Diagnosis
- 10.3.2 Personalized Medicine
- 10.3.3 Research
- 10.3.4 Clinical Trials
- 10.4 West Europe Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2024-2030]
- 10.5 West Europe Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2024-2030]
- 10.6 West Europe Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2024-2030]
Chapter 11 : Central & Eastern Europe Liquid Tumor Biopsy Market Breakdown by Country, Type & Application
- 11.1 Central & Eastern Europe Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 11.1.1 Bulgaria
- 11.1.2 Poland
- 11.1.3 Hungary
- 11.1.4 Romania
- 11.1.5 Rest of CEE
-
11.2 Central & Eastern Europe Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 11.2.1 Circulating Tumor Cells (CTC)
- 11.2.2 CtDNA
- 11.2.3 Exosomes
- 11.2.4 Liquid Biopsy Platforms
- 11.2.5 NGS-based Platforms
-
11.3 Central & Eastern Europe Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 11.3.1 Cancer Diagnosis
- 11.3.2 Personalized Medicine
- 11.3.3 Research
- 11.3.4 Clinical Trials
- 11.4 Central & Eastern Europe Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2024-2030]
- 11.5 Central & Eastern Europe Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2024-2030]
- 11.6 Central & Eastern Europe Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2024-2030]
Chapter 12 : Northern Europe Liquid Tumor Biopsy Market Breakdown by Country, Type & Application
- 12.1 Northern Europe Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 12.1.1 The United Kingdom
- 12.1.2 Sweden
- 12.1.3 Norway
- 12.1.4 Baltics
- 12.1.5 Ireland
- 12.1.6 Rest of Northern Europe
-
12.2 Northern Europe Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 12.2.1 Circulating Tumor Cells (CTC)
- 12.2.2 CtDNA
- 12.2.3 Exosomes
- 12.2.4 Liquid Biopsy Platforms
- 12.2.5 NGS-based Platforms
-
12.3 Northern Europe Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 12.3.1 Cancer Diagnosis
- 12.3.2 Personalized Medicine
- 12.3.3 Research
- 12.3.4 Clinical Trials
- 12.4 Northern Europe Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2024-2030]
- 12.5 Northern Europe Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2024-2030]
- 12.6 Northern Europe Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2024-2030]
Chapter 13 : Southern Europe Liquid Tumor Biopsy Market Breakdown by Country, Type & Application
- 13.1 Southern Europe Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 13.1.1 Spain
- 13.1.2 Italy
- 13.1.3 Portugal
- 13.1.4 Greece
- 13.1.5 Rest of Southern Europe
-
13.2 Southern Europe Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 13.2.1 Circulating Tumor Cells (CTC)
- 13.2.2 CtDNA
- 13.2.3 Exosomes
- 13.2.4 Liquid Biopsy Platforms
- 13.2.5 NGS-based Platforms
-
13.3 Southern Europe Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 13.3.1 Cancer Diagnosis
- 13.3.2 Personalized Medicine
- 13.3.3 Research
- 13.3.4 Clinical Trials
- 13.4 Southern Europe Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2024-2030]
- 13.5 Southern Europe Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2024-2030]
- 13.6 Southern Europe Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2024-2030]
Chapter 14 : East Asia Liquid Tumor Biopsy Market Breakdown by Country, Type & Application
- 14.1 East Asia Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 14.1.1 China
- 14.1.2 Japan
- 14.1.3 South Korea
- 14.1.4 Taiwan
- 14.1.5 Others
-
14.2 East Asia Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 14.2.1 Circulating Tumor Cells (CTC)
- 14.2.2 CtDNA
- 14.2.3 Exosomes
- 14.2.4 Liquid Biopsy Platforms
- 14.2.5 NGS-based Platforms
-
14.3 East Asia Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 14.3.1 Cancer Diagnosis
- 14.3.2 Personalized Medicine
- 14.3.3 Research
- 14.3.4 Clinical Trials
- 14.4 East Asia Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2024-2030]
- 14.5 East Asia Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2024-2030]
- 14.6 East Asia Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2024-2030]
Chapter 15 : Southeast Asia Liquid Tumor Biopsy Market Breakdown by Country, Type & Application
- 15.1 Southeast Asia Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 15.1.1 Vietnam
- 15.1.2 Singapore
- 15.1.3 Thailand
- 15.1.4 Malaysia
- 15.1.5 Indonesia
- 15.1.6 Philippines
- 15.1.7 Rest of SEA Countries
-
15.2 Southeast Asia Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 15.2.1 Circulating Tumor Cells (CTC)
- 15.2.2 CtDNA
- 15.2.3 Exosomes
- 15.2.4 Liquid Biopsy Platforms
- 15.2.5 NGS-based Platforms
-
15.3 Southeast Asia Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 15.3.1 Cancer Diagnosis
- 15.3.2 Personalized Medicine
- 15.3.3 Research
- 15.3.4 Clinical Trials
- 15.4 Southeast Asia Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2024-2030]
- 15.5 Southeast Asia Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2024-2030]
- 15.6 Southeast Asia Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2024-2030]
Chapter 16 : South Asia Liquid Tumor Biopsy Market Breakdown by Country, Type & Application
- 16.1 South Asia Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 16.1.1 India
- 16.1.2 Bangladesh
- 16.1.3 Others
-
16.2 South Asia Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 16.2.1 Circulating Tumor Cells (CTC)
- 16.2.2 CtDNA
- 16.2.3 Exosomes
- 16.2.4 Liquid Biopsy Platforms
- 16.2.5 NGS-based Platforms
-
16.3 South Asia Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 16.3.1 Cancer Diagnosis
- 16.3.2 Personalized Medicine
- 16.3.3 Research
- 16.3.4 Clinical Trials
- 16.4 South Asia Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2024-2030]
- 16.5 South Asia Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2024-2030]
- 16.6 South Asia Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2024-2030]
Chapter 17 : Central Asia Liquid Tumor Biopsy Market Breakdown by Country, Type & Application
- 17.1 Central Asia Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 17.1.1 Kazakhstan
- 17.1.2 Tajikistan
- 17.1.3 Others
-
17.2 Central Asia Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 17.2.1 Circulating Tumor Cells (CTC)
- 17.2.2 CtDNA
- 17.2.3 Exosomes
- 17.2.4 Liquid Biopsy Platforms
- 17.2.5 NGS-based Platforms
-
17.3 Central Asia Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 17.3.1 Cancer Diagnosis
- 17.3.2 Personalized Medicine
- 17.3.3 Research
- 17.3.4 Clinical Trials
- 17.4 Central Asia Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2024-2030]
- 17.5 Central Asia Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2024-2030]
- 17.6 Central Asia Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2024-2030]
Chapter 18 : Oceania Liquid Tumor Biopsy Market Breakdown by Country, Type & Application
- 18.1 Oceania Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 18.1.1 Australia
- 18.1.2 New Zealand
- 18.1.3 Others
-
18.2 Oceania Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 18.2.1 Circulating Tumor Cells (CTC)
- 18.2.2 CtDNA
- 18.2.3 Exosomes
- 18.2.4 Liquid Biopsy Platforms
- 18.2.5 NGS-based Platforms
-
18.3 Oceania Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 18.3.1 Cancer Diagnosis
- 18.3.2 Personalized Medicine
- 18.3.3 Research
- 18.3.4 Clinical Trials
- 18.4 Oceania Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2024-2030]
- 18.5 Oceania Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2024-2030]
- 18.6 Oceania Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2024-2030]
Chapter 19 : MEA Liquid Tumor Biopsy Market Breakdown by Country, Type & Application
- 19.1 MEA Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 19.1.1 Turkey
- 19.1.2 South Africa
- 19.1.3 Egypt
- 19.1.4 UAE
- 19.1.5 Saudi Arabia
- 19.1.6 Israel
- 19.1.7 Rest of MEA
-
19.2 MEA Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 19.2.1 Circulating Tumor Cells (CTC)
- 19.2.2 CtDNA
- 19.2.3 Exosomes
- 19.2.4 Liquid Biopsy Platforms
- 19.2.5 NGS-based Platforms
-
19.3 MEA Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 19.3.1 Cancer Diagnosis
- 19.3.2 Personalized Medicine
- 19.3.3 Research
- 19.3.4 Clinical Trials
- 19.4 MEA Liquid Tumor Biopsy Market by Country (USD Million) & Sales Volume (Units) [2024-2030]
- 19.5 MEA Liquid Tumor Biopsy Market by Type (USD Million) & Sales Volume (Units) [2024-2030]
- 19.6 MEA Liquid Tumor Biopsy Market by Application (USD Million) & Sales Volume (Units) [2024-2030]
Chapter 20: Research Findings & Conclusion
- 20.1 Key Findings
- 20.2 Conclusion
Chapter 21: Methodology and Data Source
-
21.1 Research Methodology & Approach
- 21.1.1 Research Program/Design
- 21.1.2 Market Size Estimation
- 21.1.3 Market Breakdown and Data Triangulation
-
21.2 Data Source
- 21.2.1 Secondary Sources
- 21.2.2 Primary Sources
Chapter 22: Appendix & Disclaimer
- 22.1 Acronyms & bibliography
- 22.2 Disclaimer
Frequently Asked Questions (FAQ):
The Global Liquid Tumor Biopsy market size surpassed USD2 billion in 2023 and will expand at a CAGR of 14.00% between 2023 and 2030.
The Liquid Tumor Biopsy Market is estimated to grow at a CAGR of 14.00%, currently pegged at USD2 billion.
The changing dynamics and trends such as Shift Towards Non-invasive Diagnostics, Development Of Personalized Therapies are seen as major Game Changer in Global Liquid Tumor Biopsy Market.
The leaders in the Global Liquid Tumor Biopsy Market such as Guardant Health, GRAIL, Foundation Medicine, Biocept, Cynvenio, Exact Sciences, Veracyte, Caris Life Sciences, Sysmex, NeoGenomics, Roche, Illumina, Thermo Fisher Scientific, Qiagen, ArcherDX are targeting innovative and differentiated growth drivers some of them are Adoption Of Liquid Biopsy For Early-stage Cancer Detection, Integration With AI Technologies
Some of the major roadblocks that industry players have identified are Regulatory Approval Hurdles, High Cost Of Tests.
The market opportunity is clear from the flow of investment into Global Liquid Tumor Biopsy Market, some of them are Adoption Of Liquid Biopsy For Early-stage Cancer Detection, Integration With AI Technologies.
Liquid Tumor Biopsy Market identifies market share by players along with the concentration rate using CR4, CR8 Index to determine leading and emerging competitive players such as Guardant Health, GRAIL, Foundation Medicine, Biocept, Cynvenio, Exact Sciences, Veracyte, Caris Life Sciences, Sysmex, NeoGenomics, Roche, Illumina, Thermo Fisher Scientific, Qiagen, ArcherDX.
The Global Liquid Tumor Biopsy Market Study is Broken down by applications such as Cancer Diagnosis, Personalized Medicine, Research, Clinical Trials.
The Global Liquid Tumor Biopsy Market Study is segmented by Circulating Tumor Cells (CTC), ctDNA, Exosomes, Liquid Biopsy Platforms, NGS-based Platforms.
The Global Liquid Tumor Biopsy Market Study includes regional breakdown as North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA
Historical Year: 2019 - 2023; Base year: 2023; Forecast period: 2025 to 2030
Non-invasive diagnostic tests that analyze bodily fluids to detect cancer markers.
